Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bisoprolol for prevention of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer
IRCT20250410065283N2Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bisoprolol in breast cancer and Cardiotoxicity, sponsored by Shiraz University of Medical Sciences. Primary endpoint: Incidence of trastuzumab-induced cardiotoxicity. Started Dec 2025; status: completed.
02
Drugs
bisoprolol
03
Conditions
breast cancerCardiotoxicity
Beyond the preview
Go deeper on IRCT20250410065283N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250410065283N2.